Abstract
Treatment for neoplastic Barrett’s esophagus (BE) has shifted from surgical esophagectomy to endoscopic eradication therapy. Endoscopic therapy consisting of resection of raised lesions combined with ablation of flat disease is now the mainstay of treatment for Barrett’s esophagus with dysplasia and intramucosal carcinoma. There is limited data on whether these therapies have helped decrease the rate of esophagectomy across the United States. The aim of the study was to evaluate the rate of esophagectomy for BE pre and post era of endoscopic ablative therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
